Neutralizing antiviral antibody responses

Advances in Immunology

Volumn 79, Issue , 2001, Pages 1-53

  Zinkernagel, R M ^a   LaMarre, A ^a   Ciurea, A ^a   Hunziker, L ^a   Ochsenbein, A F ^a   McCoy, K D ^a   Fehr, T ^a   Bachmann, M F ^a   Kalinke, U ^a   Hengartner, H ^a  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; FC RECEPTOR; HAPTEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY;

ADOPTIVE TRANSFER; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; AUTOIMMUNITY; BINDING AFFINITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION;

EID: 17944363478     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(01)79001-3     Document Type: Review

References (364)

1. Mls - A retrovirus exploits the immune system
2. HIV and pandemic influenza virus: Two great infectious disease challenges
3. Disruption of the Cr2 locus results in a reduction in B-Ia cells and in an impaired B cell response to T-dependent antigen
4. Immunological memory against viruses
5. Immunological memory and protective immunity: Understanding their relation
6. Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology
7. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
8. Antibody response to pre-S2 and hepatitis B virus induced liver damage
9. Immunosuppression by lymphocytic choriomeningitis virus infection: Competent effector T and B cells but impaired antigen presentation
10. Splenic dependence of the antibody response to thymus-independent (TI-2) antigens
11. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies
12. Human immunization in developing countries: Practical and theoretical problems and prospects
13. Natural autoantibodies: From 'horror autotoxicus' to 'gnothi seauton'
14. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
15. The influence of virus structure on antibody responses and virus serotype formation
16. Neutralizing antiviral B cell responses
17. The influence of antigen organization on B cell responsiveness
18. Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen
19. How many specific B cells are needed to protect against a virus?
20. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells
21. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction?
22. Correlation of tolerogenicity of a viral antigen with its immunogenicity
23. The role of antibody concentration and avidity in antiviral protection
24. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"?
25. Influenza virus: A novel method to assess viral and neutralizing antibody titers in vitro
26. A model in mice for the pathogenesis and treatment of rabies
27. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: Mother-to-baby transfer of humoral protection
28. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells
29. Self tolerance in the B-cell repertoire
30. Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells
31. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells
32. + T-cell-deficient mice
33. A two-phase model of B-cell activation
34. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection
35. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum
36. Edmonston-Zagreb measles vaccine: A good vaccine with an image problem
37. The morphological and biological effects of various antisera on avian infectious bronchitis virus
38. The immunopathology of acute type B hepatitis
39. Immunohistopathology of lymph nodes in HTLV-III infected homosexuals with persistent adenopathy or AIDS
40. Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis
41. Virus-induced transient bone marrow aplasia: Major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus
42. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence
43. Immunity to infection
44. The death and resurrection of tuberculosis
45. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM
46. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection
47. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients
48. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age
49. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection
50. Virus-induced immunosuppression: Immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression
51. B cell repertoire in adult antigen-free and conventional neonatal BALB/c mice. I. Preferential utilisation of the CH-proximal VH gene family PC7183
52. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites
53. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors
54. Overview of the mucosal immune system
55. A theory of self-nonself discrimination
56. Defects in the immune system of mice infected with lymphocytic choriomeningitis virus
57. Use of peptides for immunization against foot-and-mouth disease
58. Immunity to viruses in B cell deficient mice: Influence of antibodies on virus-persistence and on T cell memory
59. Humoral immune responses against particulate bacterial antigens are dependent on marginal metallophilic macrophages in the spleen
60. A prospective study of dengue infections in Bangkok
61. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys
62. Glycoproteins of the arenaviruses
63. Antibody and virus: Binding and neutralization
64. New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL)
65. Vaccine-induced escape mutant of hepatitis B virus
66. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA
67. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis
68. + T-cell counts and T-cell function in long-term AIDS-free infection
69. The role of complement and complement receptors in induction and regulation of immunity
70. + B lymphocytes, polyreactive antibodies and the human B-cell repertoire
71. A quasi-monoclonal mouse
72. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles
73. Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus
74. Immunoglobulin heavy chain gene replacement: A mechanism of receptor editing
75. Editing disease-associated autoantibodies
76. Neuropathogenicity and sensitivity to antibody neutralization of lactate dehydrogenase-elevating virus are determined by polylactosaminoglycan chains on the primary envelope glycoprotein
77. Hepatitis B virus immunopathogenesis
78. Identification of gp 120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate
79. Host immune response to vesicular stomatitis virus infection of the central nervous system in C57BL/6 mice
80. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice
81. Viral persistence in vivo through selection of neutralizing antibody-escape variants
82. + T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants
83. The BALB/c secondary response to the Sb site of influenza virus hemagglutinin. Non-random silent mutation and equal numbers of VH and Vk mutations
84. V region gene usage and somatic mutation in the primary and secondary responses to influenza virus hemagglutinin
85. Regulation of autoimmune disease physiological and therapeutic
86. The protection: The unit of humoral immunity selected by evolution
87. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens
88. Complement evasion strategies of microorganisms
89. Complement, viruses, and virus-infected cells
90. The role of antibody and complement in the control of viral infections
91. Beyond clonal selection and network
92. Natural antibodies
93. Thymus-independent B-cell induction and paralysis
94. Global epidemiology of influenza: Past and present
95. Fc receptor biology
96. A multi-hit model for the neutralization of animal viruses
97. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
98. Antigenic variation and resistance to neutralization in poliovirus type 1
99. Evolution of somatic hypermutation and gene conversion in adaptive immunity
100. Biological characterization of human monoclonal antibodies to rabies virus
101. Mechanisms of neutralization of animal viruses
102. Neutralization of animal viruses
103. Molecular determinants of immunogenicity: The immunon model of immune response
104. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence
105. RNA virus mutations and fitness for survival
106. New observations on antigenic diversification of RNA viruses. Antigenic variation is not dependent on immune selection
107. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus
108. Inhibition of influenzaimmune T cell effector function by virus-specific hybridoma antibody
109. Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response
110. Variations in affinities of antibodies during the immune response
111. Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization
112. Maternal immunization against viral disease
113. Persistence of tetanus antitoxin in man following active immunisation
114. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing
115. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
116. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
117. The joint evolution of antigens and antibodies
118. Methods in immunochemistry of viruses. I. Equilibrium filtration
119. Disquisitions on original antigenic sin. I: Evidence in man
120. Disquisitions on original antigenic sin. II: Proof in lower creatures
121. The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity
122. The instructive role of innate immunity in the acquired immune response
123. T-independent activation of B cells by vesicular stomatitis virus: No evidence for the need of a second signal
124. Role of repetitive antigen patterns for induction of antibodies against antibodies
125. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses
126. Antiviral protection and germinal center formation, but impaired B cell memory in the absence of CD19
127. Correlation of anti-viral B cell responses and splenic morphology with expression of B cell-specific molecules
128. Mousepox (infectious ectromelia of mice): A review
129. Dependence of germinal center B cells on expression of CD21/CD35 for survival
130. Mechanisms of rabies virus neutralization
131. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor
132. A serological recapitulation of human infection with different strains of influenza virus
133. Potential strategies utilised by papillomavirus to evade host immunity
134. Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen
135. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I
136. Mathematical model of a virus-neutralizing immunglobulin response
137. Child mortality after high-titre measles vaccines: Prospective study in Senegal
138. Receptor editing: An approach by autoreactive B cells to escape tolerance
139. Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle
140. An outbreak of mumps in a population partially vaccinated with the Rubini strain
141. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus
142. Lack of significant differences in association rates and affinities of antibodies from short-term and long-term responses to hen egg lysozyme
143. Disturbances in gamma globulin synthesis as experiments of nature
144. Induction of self-tolerance in mature peripheral B lymphocytes
145. Immunodeficiency measles encephalitis
146. Immunological memory
147. Primary antibody responses to a well-defined and unique hapten are not enhanced by preimmunization with carrier: Analysis in a viral model
148. Health inequalities and the health of the poor: What do we know? What can we do?
149. Pathogenesis of dengue: Challenges to molecular biology
150. V(D)J recombinase activity in a subset of germinal center B lymphocytes
151. Elimination of self-reactive B lymphocytes proceeds in two stages: Arrested development and cell death
152. The repertoire of serum IgM in normal mice is largely independent of external antigenic contact
153. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls
154. V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling
155. B-cell lineages exist in the mouse
156. Rapid evolution of RNA genomes
157. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells
158. The biology of lymphocytic choriomeningitis infection: Virus induced immune disease
159. Protection against the lethal effect of lymphocytic choriomeningitis virus in mice by neonatal thymectomy
160. Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population
161. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis
162. Mechanisms of neutralization of animal viruses: Monoclonal antibodies provide a new perspective
163. Enumeration of antigenic sites of influenza virus hemagglutinin
164. Lymphocytic choriomeningitis virus-induced immunosuppression: A virus-induced macrophage defect
165. An immunohistochemical study on organized lymphoid cell infiltrates in fetal and neonatal pancreases. A comparison with similar infiltrates found in the pancreas of a diabetic infant
166. A study of avidity based on rabbit skin responses to diphteria toxin-antitoxin mixtures
167. Idiotypic networks and other preconceived ideas
168. Pathogenesis of viral infections of the nervous system
169. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
170. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus (VSV)
171. Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus (VSV) protect against lethal infection
172. Virus neutralization by germ-line vs. hypermutated antibodies
173. Poliovirus mutants resistant to neutralization with soluble cell receptors
174. Detection of measles virus nucleoprotein mRNA in autopsied brain tissues
175. The regulatory influence of activated T cells on B cell responses to antigen
176. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression
177. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene
178. T cell-independent rescue of B lymphocytes from peripheral immune tolerance
179. Fibroblasts as efficient antigen-presenting cells in lymphoid organs
180. On the role of antigen in maintaining cytotoxic T-cell memory
181. A single amino acid in the glycosyl phosphatidylinositol attachment domain determines the membrane topology of Fc gamma RIII
182. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
183. Complement and immunity to viruses
184. The interaction between virus and antibody. II. Mechanism of the reaction
185. Protection from lethal coronavirus infection by immunoglobulin fragments
186. A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice
187. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: A possible mechanism for antigenic drift
188. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen
189. Two signal models of lymphocyte activation?
190. Epitopes on protein antigens: Misconceptions and realities
191. Hepatitis B virus infection
192. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: Distinct mechanisms of action in vivo
193. Antigenic determinants of vesicular stomatitis virus: Analysis with antigenic variants
194. Lymphocytic choriomeningitis virus
195. Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells
196. Antibody-mediated clearance of alphavirus infection from neurons
197. Immune serum increases arenavirus replication in monocytes
198. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity
199. Secondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses
200. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue
201. Role of dendritic cells in the induction and maintenance of autoimmune diseases
202. Point mutations in glycoprotein gene of vesicular stomatitis virus (New Jersey serotype) selected by resistance to neutralization by epitope-specific monoclonal antibodies
203. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes
204. Cellular resistance to infection
205. The immunological basis of acquired cellular resistance
206. The influence of immunologically committed lymphoid cells on macrophage activity in vivo
207. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria
208. Measles epidemic in the urban community of Niamey: Transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991
209. Neutralization of poliovirus: A hypothesis to explain the mechanism and the one-hit character of the neutralization reaction
210. Survival of long-lived plasma cells is independent of antigen
211. Memory B-cell persistence is independent of persisting immunizing antigen
212. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
213. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials
214. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
215. Implications of a quasispecies genome structure: Effect of frequent, naturally occurring amino acid substitutions on the antigenicity foot-and-mouth disease virus
216. + cytotoxic T-cell responses during chronic viral infection
217. Tolerance, danger, and the extended family
218. Virus-induced immunosuppression: Infections with measles virus and human immunodeficiency virus
219. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells
220. Antigen receptor engagement turns off the V(D)J recombination machinery in human tonsil B cells
221. Hepatitis B virus persistence after recovery from acute viral hepatitis
222. Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis
223. Pathogenesis of lesions in lymphoid tissue of mice infected with lymphocytic choriomeningitis (LCM) virus
224. The immunodepressive action of lymphocytic choriomeningitis virus in mice
225. The carrier effect in the secondary response to hapten-protein conjugates. V. Use of antilymphocyte serum to deplete animals of helper cells
226. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis
227. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2
228. One non-specific signal triggers B lymphocytes
229. Mechanisms of liver cell injury in acute and chronic hepatitis
230. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
231. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
232. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1
233. Antibody-dependent enhancement of infection and the pathogenesis of viral disease
234. Antiviral antibody-producing cells in parenchymatous organs during persistent virus infection
235. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro
236. Clonal expansion versus functional clonal inactivation: A constimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
237. Rabies pathogenesis
238. The epidemiology of poliomyelitis: Enigmas surrounding its appearance, epidemicity, and disappearance
239. Receptor editing in B cells
240. Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras
241. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class antibody genes
242. Clonal deletion of autospecific B lymphocytes
243. Cellular mechanisms of immunologic tolerance
244. Vaccines
245. Antigens in immunity: VII. Analysis of immunological memory
246. Natural antibodies and complement link innate and acquired immunity
247. Control of early viral and bacterial distribution and disease by natural antibodies
248. Protective T cell-independent antiviral antibody responses are dependent on complement
249. Correlation of T cell independence of antibody responses with antigen dose reaching secondary lymhoid organs: Implications for splenectomized patients and vaccine design
250. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs
251. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure
252. Vaccination for disease
253. The control of measles in tropical Africa: A review of past and present efforts
254. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus
255. Lymphocytic choriomeningitis: Production of antibody by "tolerant" infected mice
256. Virus-induced immune complex disease: Specific anti-viral antibody and C1q binding material in the circulation during persistent lymphocytic choriomeningitis virus infection
257. Virus-specific MHC class II-restricted TCR-transgenic mice: Effects on humoral and cellular immune responses after viral infection
258. + T cell functions
259. + T-cell induction and effector functions: A comparison of immunity against soluble antigens and viral infections
260. + T cells upon acute versus persistent viral infection
261. V(D)J recombination in mature B cells: A mechanism for altering antibody responses
262. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
263. Receptor editing in a transgenic mouse model: Site, efficiency and role in B cell tolerance and antibody diversification
264. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
265. Lactate dehydrogenaseelevating virus: An ideal persistent virus?
266. Specific cytotoxic T cells eliminate cells producing neutralizing antibodies
267. + T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers
268. Antibody neutralization of HIV-1
269. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
270. Antibody-dependent enhancement of viral infectivity
271. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
272. Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes
273. B lymphocytes may escape tolerance by revising their antigen receptors
274. Fc receptors: Rubor redux
275. Divergent roles for Fc receptors and complement in vivo
276. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response
277. Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b
278. A role for carbohydrates in immune evasion in AIDS
279. Antigen receptor tail clue
280. An unsolved problem of the clonal selection theory and the model of an oligomeric B-cell antigen receptor
281. Hepatitis C virus
282. Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficieney virus infections
283. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
284. Analysis of the kinetics of antiviral memory T help in vivo: Characterization of short-lived cross-reactive T help
285. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity
286. Mapping of the dominant neutralizing antigenic site of a virus using infected cells
287. Studies on pathogenesis and immunity in lymphocytic choriomeningitis infection of the mouse
288. Live attenuated AIDS viruses as vaccines: Promise or peril?
289. Paralytic poliomyelitis: Old dogmas and new perspectives
290. Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world
291. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines
292. Human immunodeficiency virus type 1 incorporates both glycosyl phoshatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction
293. Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants
294. Spontaneous mutation rate of measles virus: Direct estimation based on mutations conferring monoclonal antibody resistance
295. Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils
296. Acquisition of immunologic self-tolerance
297. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection
298. In vivo selection of neutralization-resistant virus variants but no evidence of B cell tolerance in lymphocytic choriomeningitis virus carrier mice expressing a transgenic virus-neutralizing antibody
299. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells
300. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
301. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
302. Influence of maternal antibodies on vaccine responses: Inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice
303. Mechanisms of hemopoietic and immunological dysfunction induced by lymphocytic choriomeningitis virus
304. Antibody-independent activation of the alternative complement pathway by measles virus-infected cells
305. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by monoclonal antibody
306. Long-lived plasma cells: A mechanism for maintaining persistent antibody production
307. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon
308. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin
309. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice
310. Recent structural solutions for antibody neutralization of viruses
311. Mumps epidemic in vaccinated children in West Switzerland
312. Helper T cell memory: More questions than answers
313. Electron microscopic and immunochemical studies in a patient with hepatitis C virus infection and mixed cryoglobulinemia type II
314. Antibody-enhanced infection by HIV-1 via Fe receptor-mediated entry
315. Autoimmune disease and the theory of clonal abortion. Is it still relevant?
316. Follicular dendritic cells as accessory cells
317. Risk factors in dengue shock syndrome
318. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice
319. Receptor editing in self-reactive bone marrow B cells
320. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation
321. Virus-induced immunosuppression. 1. Age at infection relates to a selective or generalized defect
322. Autoimmunity: From physiology to pathology. Natural antibodies, mucosal immunity and development of B cell repertoire
323. Somatic generation of antibody diversity
324. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera
325. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
326. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
327. Dual antigen recognition by B cells
328. Diabetes, autoimmunity, and arteriosclerosis
329. Uber das zustandekommen der diphterie-immunitat und der tetanus-immunitat bei thieren
330. Virus aggregation as the cause of the non-neutralizable persistent fraction
331. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera
332. Influenza virus A pathogenicity: The pivotal role of hemagglutinin
333. Molecular mechanisms of variation in influenza viruses
334. Immunological unresponsivenes
335. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
336. Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever
337. Human serum lyses RNA tumour viruses
338. Factors affecting the immunogenicity of oral poliovirus vaccine: A prospective evaluation in Brazil and the Gambia
339. Measles vaccines, new developments and immunization strategies
340. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation
341. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia
342. Structural basis of immune recognition of influenza virus hemagglutinin
343. Epitopes involved in antibody-mediated protection from Ebola virus
344. Receptor revision of immunoglobulin heavy chain variable region genes in normal human B lymphocytes
345. Neutralizing epitopes of lymphocytic choriomeningitis virus are conformational and require both glycosylation and disulfide bonds for expression
346. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
347. Antigenic variation in three distinct determinants of an influenza type HA molecule
348. On immunological memory
349. What is missing in immunology to understand immunity?
350. Virus-induced autoantibody response to a transgenic viral antigen
351. T and B cell tolerance and responses to viral antigens in transgenic mice: Implications for the pathogenesis of autoimmune versus immunopathological disease
352. On immunological memory
353. General and specific immunosuppression caused by antiviral T-cell responses
354. Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses